Document text
Principal Investigator: Galit Alter
Organization: MASSACHUSETTS GENERAL HOSPITAL
Fiscal Year: 2021
Award: $348,242
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract
The robust protection conferred by emerging EUA approved SARS-CoV-2 vaccines represents a critical milestone in COVID-19 vaccine development. However, the emergence of variants has inspired renewed concern related to the protective efficacy of currently approved vaccines, which lose neutralizing potency against some variants. However, emerging data suggest that antibody functions, beyond neutralization, that emerge early after vaccination and that persist even with a loss of neutralization, may contribute to protection from disease. Thus, here we aim to profile the evolution of the breadth of the VOC-specific Fc-effector functions of vaccine induced antibodies across vaccine platforms. Specifically, we aim to profile the subclass, isotypes, Fc-receptor binding, complement depositing function, cellular cytotoxicity, opsinophagocytic activity, degranulation, and mucus trapping days after vaccination compared to convalescent individuals. These data will be compared to breakthrough infection cases from Novavax (& Medicago) and J&J.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Acute Nasopharyngitis><Adenoviridae><Adenoviruses><Adjuvant><Affect><Antibodies><Antibody Response><Antigens><Antiviral Agents><Antiviral Drugs><Antivirals><Area><Benign><Binding><Blood Neutrophil><Blood Polymorphonuclear Neutrophil><Blood monocyte><COVID-19><COVID-19 immunity><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 immunity><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell-Mediated Cytolysis><Cell-Mediated Lympholysis><Cellular Cytotoxicity><Cellular Immune Function><CoV-2><CoV2><Common Cold><Complement><Complement Proteins><Cytotoxic cell><DNA><Data><Deoxyribonucleic Acid><Deposit><Deposition><Detection><Disease><Disorder><Ebola><Evolution><FDA EUA><FDA Emergency Use Authorization><Fc Receptor><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Genetic Alteration><Genetic Change><Genetic defect><Geographic Area><Geographic Locations><Geographic Region><Geographical Location><Grippe><HIV><Human Immunodeficiency Viruses><Immune><Immune response><Immunes><Immunity><Immunize><Immunological response><Individual><Infection><Infection prevention><Influenza><Influenza Virus><Innate Immune System><Innate Immunity><K lymphocyte><LAV-HTLV-III><Link><Long-term cohort><Longitudinal cohort><Longterm cohort><Lymphadenopathy-Associated Virus><Lymphocyte Cytotoxicity><Lymphocytotoxicity><Lytotoxicity><Marrow Neutrophil><Marrow monocyte><Mediating><Medicago><Messenger RNA><Molecular Interaction><Mucous body substance><Mucus><Mutation><NK Cells><Native Immunity><Natural Immunity><Natural Killer Cells><Neutrophilic Granulocyte><Neutrophilic Leukocyte><Non-Specific Immunity><Nonspecific Immunity><Phagocytosis><Phase 2/3 trial><Phase II/III Trial><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Prevent infection><Proteins><RNA vaccine><RNA-based vaccine><Receptor Protein><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 immunity><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serotyping><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Site><Surface><T-Cells><T-Lymphocyte><Testing><Time><Transmission><Vaccinated><Vaccination><Vaccines><Variant><Variation><Viral Diseases><Virus><Virus Diseases><Virus-HIV><Work><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral drugs><anti-virals><antibody receptor><base><cell mediated cytotoxicity><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 immunity><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><cytotoxicity><decline in function><decline in functional status><develop a vaccine><development of a vaccine><disease severity><emergency use authorization><functional decline><functional status decline><genome mutation><geographic site><hCoV19><host response><immune function><immune system response><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunogen><immunoresponse><improved><influenzavirus><insight><mRNA><mRNA vaccine><mRNA-based vaccine><monocyte><mucous><nCoV2><neutralizing antibody><neutrophil><next generation><non-human primate><nonhuman primate><parent grant><phase 3 trial><phase III trial><prevent><preventing><protective efficacy><public health relevance><receptor><receptor binding><receptor bound><response><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><thymus derived lymphocyte><transmission process><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine antibodies><vaccine development><vaccine for novel coronavirus><vaccine formulation><vaccine induced antibodies><vaccine-induced antibodies><variants of concern><vector><viral infection><virus infection><virus-induced disease>